ロード中...
KRAS-Driven Metabolic Rewiring Reveals Novel Actionable Targets in Cancer
Tumors driven by mutant KRAS are among the most aggressive and refractory to treatment. Unfortunately, despite the efforts, targeting alterations of this GTPase, either directly or by acting on the downstream signaling cascades, has been, so far, largely unsuccessful. However, recently, novel therap...
保存先:
| 出版年: | Front Oncol |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6730590/ https://ncbi.nlm.nih.gov/pubmed/31544066 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.00848 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|